The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery.

In a perfect sequence of events, nanoparticles (NPs) are injected into the bloodstream where they circulate until they reach the target tissue. The ligand on the NP surface recognizes its specific receptor expressed on the target tissue and the drug is released in a controlled manner. However, once injected in a physiological environment, NPs interact with biological components and are surrounded by a protein corona (PC). This can trigger an immune response and affect NP toxicity and targeting capabilities. In this review, we provide a survey of recent findings on the NP-PC interactions and discuss how the PC can be used to modulate both cytotoxicity and the immune response as well as to improve the efficacy of targeted delivery of nanocarriers.

[1]  M. Ferrari,et al.  The nano-plasma interface: Implications of the protein corona. , 2014, Colloids and surfaces. B, Biointerfaces.

[2]  Giulio Caracciolo,et al.  Evolution of the protein corona of lipid gene vectors as a function of plasma concentration. , 2011, Langmuir : the ACS journal of surfaces and colloids.

[3]  Minnamari Vippola,et al.  Proteomic characterization of engineered nanomaterial-protein interactions in relation to surface reactivity. , 2011, ACS nano.

[4]  E. Tasciotti,et al.  Proteomic Profiling of a Biomimetic Drug Delivery Platform. , 2014, Current drug targets.

[5]  Wolfgang Tremel,et al.  A plasma protein corona enhances the biocompatibility of Au@Fe3O4 Janus particles. , 2015, Biomaterials.

[6]  Giulio Caracciolo,et al.  Surface chemistry and serum type both determine the nanoparticle-protein corona. , 2015, Journal of proteomics.

[7]  M. Dobrovolskaia,et al.  Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics , 2015, Expert opinion on drug delivery.

[8]  Giulio Caracciolo,et al.  Analysis of plasma protein adsorption onto DC-Chol-DOPE cationic liposomes by HPLC-CHIP coupled to a Q-TOF mass spectrometer , 2010, Analytical and bioanalytical chemistry.

[9]  ラン ラン,et al.  Interview ラン・ラン , 2014 .

[10]  R. Müller,et al.  Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption. , 2000, International journal of pharmaceutics.

[11]  Young-Rok Kim,et al.  The fate of calcium carbonate nanoparticles administered by oral route: absorption and their interaction with biological matrices , 2015, International journal of nanomedicine.

[12]  Candace C. Fleischer,et al.  Secondary Structure of Corona Proteins Determines the Cell Surface Receptors Used by Nanoparticles , 2014, The journal of physical chemistry. B.

[13]  C. Casals,et al.  Uptake of nanoparticles by alveolar macrophages is triggered by surfactant protein A. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[14]  V. Kadam,et al.  Drug loaded erythrocytes: as novel drug delivery system. , 2008, Current pharmaceutical design.

[15]  Anne L. van de Ven,et al.  Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. , 2013, Nature nanotechnology.

[16]  Mark B. Carter,et al.  Erratum: The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers (Nature Materials (2011) 10 (389-397)) , 2011 .

[17]  Ching-Seng Ang,et al.  Monoclonal antibody-functionalized multilayered particles: targeting cancer cells in the presence of protein coronas. , 2015, ACS nano.

[18]  Chandana Mohanty,et al.  Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. , 2012, Drug discovery today.

[19]  Lisa Brannon-Peppas,et al.  Active targeting schemes for nanoparticle systems in cancer therapeutics. , 2008, Advanced drug delivery reviews.

[20]  V. Torchilin.  Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery , 2014, Nature Reviews Drug Discovery.

[21]  Albert Duschl,et al.  Hardening of the nanoparticle-protein corona in metal (Au, Ag) and oxide (Fe3O4, CoO, and CeO2) nanoparticles. , 2011, Small.

[22]  Marco P Monopoli,et al.  Biomolecular coronas provide the biological identity of nanosized materials. , 2012, Nature nanotechnology.

[23]  Ronald J. Moore,et al.  Quantitative proteomics analysis of adsorbed plasma proteins classifies nanoparticles with different surface properties and size , 2011, Proteomics.

[24]  Vladimir R Muzykantov,et al.  Drug delivery by red blood cells: vascular carriers designed by mother nature , 2010, Expert opinion on drug delivery.

[25]  K. Brown,et al.  A Liposomal Drug Platform Overrides Peptide Ligand Targeting to a Cancer Biomarker, Irrespective of Ligand Affinity or Density , 2013, PloS one.

[26]  Daniella Yeheskely-Hayon,et al.  High levels of reactive oxygen species in gold nanoparticle-targeted cancer cells following femtosecond pulse irradiation , 2013, Scientific Reports.

[27]  Mark E. Davis.  The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. , 2009, Molecular pharmaceutics.

[28]  Ronnie H. Fang,et al.  Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery , 2014, Nano letters.

[29]  G. Caracciolo,et al.  The liposome-protein corona in mice and humans and its implications for in vivo delivery. , 2014, Journal of materials chemistry. B.

[30]  J. Vallée,et al.  Ex situ evaluation of the composition of protein corona of intravenously injected superparamagnetic nanoparticles in rats. , 2014, Nanoscale.

[31]  Iseult Lynch,et al.  Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. , 2011, Journal of the American Chemical Society.

[32]  Marilena Hadjidemetriou,et al.  In Vivo Biomolecule Corona around Blood-Circulating, Clinically Used and Antibody-Targeted Lipid Bilayer Nanoscale Vesicles. , 2015, ACS nano.

[33]  Mingdong Huang,et al.  Elucidation of the Contribution of Active Site and Exosite Interactions to Affinity and Specificity of Peptidylic Serine Protease Inhibitors Using Non-Natural Arginine Analogs , 2011, Molecular Pharmacology.

[34]  Darren J. Martin,et al.  Differential plasma protein binding to metal oxide nanoparticles , 2009, Nanotechnology.

[35]  M. Bally,et al.  Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages. , 2001, Biochimica et biophysica acta.

[36]  Andrew Emili,et al.  Protein corona fingerprinting predicts the cellular interaction of gold and silver nanoparticles. , 2014, ACS nano.

[37]  Richard D Smith,et al.  Review, evaluation, and discussion of the challenges of missing value imputation for mass spectrometry-based label-free global proteomics. , 2015, Journal of proteome research.

[38]  C. Pitzalis,et al.  Trojan horses and guided missiles: targeted therapies in the war on arthritis , 2015, Nature Reviews Rheumatology.

[39]  Jeffrey A. Hubbell,et al.  Materials engineering for immunomodulation , 2009, Nature.

[40]  Ronnie H. Fang,et al.  Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform , 2011, Proceedings of the National Academy of Sciences.

[41]  Andrew Emili,et al.  Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. , 2012, Journal of the American Chemical Society.

[42]  C. Lagenaur,et al.  Role of CD47 as a marker of self on red blood cells. , 2000, Science.

[43]  A. Milani,et al.  Crucial role of the protein corona for the specific targeting of nanoparticles. , 2015, Nanomedicine.

[44]  P. Cullis,et al.  Liposomal drug delivery systems: from concept to clinical applications. , 2013, Advanced drug delivery reviews.

[45]  Morteza Mahmoudi,et al.  Personalized protein coronas: a "key" factor at the nanobiointerface. , 2014, Biomaterials science.

[46]  T. Webster.  Interview: Nanomedicine: past, present and future. , 2013, Nanomedicine.

[47]  Kenneth A. Dawson,et al.  Effects of the presence or absence of a protein corona on silica nanoparticle uptake and impact on cells. , 2012, ACS nano.

[48]  Stefan Tenzer,et al.  Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. , 2011, ACS nano.

[49]  Sara Linse,et al.  Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. , 2007, Angewandte Chemie.

[50]  Zhuang Liu,et al.  Drug delivery with carbon nanotubes for in vivo cancer treatment. , 2008, Cancer research.

[51]  M. Mahmoudi,et al.  Protein corona composition of gold nanoparticles/nanorods affects amyloid beta fibrillation process. , 2015, Nanoscale.

[52]  Yuliang Zhao,et al.  Nanotoxicology: Are carbon nanotubes safe? , 2008, Nature nanotechnology.

[53]  R B Sim,et al.  Proteases of the complement system. , 2004, Biochemical Society transactions.

[54]  The effects of aggregation and protein corona on the cellular internalization of iron oxide nanoparticles. , 2011, Biomaterials.

[55]  James Chen Yong Kah,et al.  Exploiting the protein corona around gold nanorods for loading and triggered release. , 2012, ACS nano.

[56]  R. Gurny,et al.  An investigation on the role of plasma and serum opsonins on the internalization of biodegradable poly(D,L-lactic acid) nanoparticles by human monocytes. , 1995, Life sciences.

[57]  H. Santos,et al.  Intravenous delivery of hydrophobin-functionalized porous silicon nanoparticles: stability, plasma protein adsorption and biodistribution. , 2012, Molecular pharmaceutics.

[58]  M. Lück,et al.  Analysis of plasma protein adsorption on polymeric nanoparticles with different surface characteristics. , 1998, Journal of biomedical materials research.

[59]  P. Charoenphol,et al.  Plasma Protein Corona Modulates the Vascular Wall Interaction of Drug Carriers in a Material and Donor Specific Manner , 2014, PloS one.

[60]  Elena Karnaukhova,et al.  The effect of protein corona composition on the interaction of carbon nanotubes with human blood platelets. , 2014, Biomaterials.

[61]  Claus-Michael Lehr,et al.  Interaction of metal oxide nanoparticles with lung surfactant protein A. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[62]  H. Sies,et al.  Role of reactive oxygen species in cell toxicity. , 1992, Toxicology letters.

[63]  Julia Gorelik,et al.  Respiratory epithelial cytotoxicity and membrane damage (holes) caused by amine-modified nanoparticles , 2012, Nanotoxicology.

[64]  Katia Perruccio,et al.  Surface hydrophobin prevents immune recognition of airborne fungal spores , 2009, Nature.

[65]  Hak Soo Choi,et al.  Rapid translocation of nanoparticles from the lung airspaces to the body , 2010, Nature Biotechnology.

[66]  Raimo Hartmann,et al.  Temperature: the "ignored" factor at the NanoBio interface. , 2013, ACS nano.

[67]  Sara Linse,et al.  Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles , 2007, Proceedings of the National Academy of Sciences.

[68]  S. Kapur,et al.  Opsonin-independent ligation of Fc gamma receptors. The 3G8-bearing receptors on neutrophils mediate the phagocytosis of concanavalin A- treated erythrocytes and nonopsonized Escherichia coli , 1987, The Journal of experimental medicine.

[69]  M. Agostini,et al.  Enabling cytoplasmic delivery and organelle targeting by surface modification of nanocarriers , 2015, Nanomedicine.

[70]  F. Salvatore,et al.  Oncoproteomic approaches to cancer marker discovery: the case of colorectal cancer , 2015 .

[71]  J. Lausmaa,et al.  Immune complement activation is attenuated by surface nanotopography , 2011, International journal of nanomedicine.

[72]  Dennis E Discher,et al.  Minimal " Self " Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles References and Notes , 2022 .

[73]  Fengjuan Wang,et al.  The biomolecular corona is retained during nanoparticle uptake and protects the cells from the damage induced by cationic nanoparticles until degraded in the lysosomes. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[74]  A. Salvati,et al.  Balancing the effect of corona on therapeutic efficacy and macrophage uptake of lipid nanocapsules. , 2015, Biomaterials.

[75]  Giulio Caracciolo,et al.  Surface adsorption of protein corona controls the cell internalization mechanism of DC-Chol-DOPE/DNA lipoplexes in serum. , 2010, Biochimica et biophysica acta.

[76]  Matthias Epple,et al.  TOXICITY OF SILVER NANOPARTICLES INCREASES DURING STORAGE BECAUSE OF SLOW DISSOLUTION UNDER RELEASE OF SILVER IONS , 2010 .

[77]  Albert Duschl,et al.  Time evolution of the nanoparticle protein corona. , 2010, ACS nano.

[78]  Thomas J Webster,et al.  Effect of the protein corona on nanoparticles for modulating cytotoxicity and immunotoxicity , 2014, International journal of nanomedicine.

[79]  T. Veenstra,et al.  The Human Plasma Proteome , 2004, Molecular & Cellular Proteomics.

[80]  S. Tope,et al.  Aptamers as therapeutics , 2013 .

[81]  S. Stolte,et al.  The nanoparticle biomolecule corona: lessons learned - challenge accepted? , 2015, Chemical Society reviews.

[82]  Ronnie H. Fang,et al.  Nanoparticle biointerfacing via platelet membrane cloaking , 2015, Nature.

[83]  M. Ferrari,et al.  Mild Hyperthermia Enhances Transport of Liposomal Gemcitabine and Improves In Vivo Therapeutic Response , 2015, Advanced healthcare materials.

[84]  R. Zhou,et al.  Binding of blood proteins to carbon nanotubes reduces cytotoxicity , 2011, Proceedings of the National Academy of Sciences.

[85]  B. Forbes,et al.  What are the biological and therapeutic implications of biomolecule corona formation on the surface of inhaled nanomedicines? , 2015, Nanomedicine.

[86]  Hideyoshi Harashima,et al.  Enhanced Hepatic Uptake of Liposomes Through Complement Activation Depending on the Size of Liposomes , 1994, Pharmaceutical Research.

[87]  C. Suri,et al.  Interaction of gold nanoparticles with protein: A spectroscopic study to monitor protein conformational changes , 2008 .

[88]  Kenneth A. Dawson,et al.  Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts , 2008, Proceedings of the National Academy of Sciences.

[89]  Pauline M Rudd,et al.  The "sweet" side of the protein corona: effects of glycosylation on nanoparticle-cell interactions. , 2015, ACS nano.

[90]  K. Langer,et al.  Comparative examination of adsorption of serum proteins on HSA- and PLGA-based nanoparticles using SDS-PAGE and LC-MS. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[91]  N. Monteiro-Riviere,et al.  Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line. , 2009, Toxicology and applied pharmacology.

[92]  Parag Aggarwal,et al.  Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. , 2009, Nanomedicine : nanotechnology, biology, and medicine.

[93]  M. Mahmoudi,et al.  Personalized disease-specific protein corona influences the therapeutic impact of graphene oxide. , 2015, Nanoscale.

[94]  Jau-Song Yu,et al.  Comprehensive proteomic analysis of mineral nanoparticles derived from human body fluids and analyzed by liquid chromatography-tandem mass spectrometry. , 2011, Analytical biochemistry.

[95]  Massimo Fresta,et al.  Physicochemical features and transfection properties of chitosan/poloxamer 188/poly(D,L-lactide-co-glycolide) nanoplexes , 2014, International journal of nanomedicine.

[96]  Véronique Préat,et al.  To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[97]  M. Ferrari,et al.  The effect of multistage nanovector targeting of VEGFR2 positive tumor endothelia on cell adhesion and local payload accumulation. , 2014, Biomaterials.

[98]  Albert Duschl,et al.  Interaction of nanoparticles with proteins: relation to bio-reactivity of the nanoparticle , 2013, Journal of Nanobiotechnology.

[99]  Mauro Ferrari,et al.  Principles of nanoparticle design for overcoming biological barriers to drug delivery , 2015, Nature Biotechnology.

[100]  J. Diederichs,et al.  Plasma protein adsorption patterns on liposomes: Establishment of analytical procedure , 1996, Electrophoresis.

[101]  H. Dai,et al.  High performance in vivo near-IR (>1 μm) imaging and photothermal cancer therapy with carbon nanotubes , 2010, Nano research.

[102]  Marcelle Machluf,et al.  Reconstructed stem cell nanoghosts: a natural tumor targeting platform. , 2013, Nano letters.

[103]  Frank A. Witzmann,et al.  Silver Nanoparticle Protein Corona Composition in Cell Culture Media , 2013, PloS one.

[104]  Giulio Caracciolo,et al.  Effect of polyethyleneglycol (PEG) chain length on the bio-nano-interactions between PEGylated lipid nanoparticles and biological fluids: from nanostructure to uptake in cancer cells. , 2014, Nanoscale.

[105]  Rassoul Dinarvand,et al.  Protein corona hampers targeting potential of MUC1 aptamer functionalized SN-38 core-shell nanoparticles. , 2015, International journal of pharmaceutics.

[106]  Ying Liu,et al.  Surface chemistry and aspect ratio mediated cellular uptake of Au nanorods. , 2010, Biomaterials.

[107]  Morteza Mahmoudi,et al.  Protein Corona Composition of Superparamagnetic Iron Oxide Nanoparticles with Various Physico-Chemical Properties and Coatings , 2014, Scientific Reports.

[108]  Chunying Chen,et al.  Reducing the cytotoxicity of ZnO nanoparticles by a pre-formed protein corona in a supplemented cell culture medium , 2015 .

[109]  Dae-Duk Kim,et al.  Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. , 2007, International journal of pharmaceutics.

[110]  Warren C W Chan,et al.  Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. , 2012, Chemical Society reviews.

[111]  G. Kenner,et al.  Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. , 2007, Biochimica et biophysica acta.

[112]  Liying Wang,et al.  Mechanisms of Nanoparticle-Induced Oxidative Stress and Toxicity , 2013, BioMed research international.

[113]  Giulio Caracciolo,et al.  Label-free quantitative analysis for studying the interactions between nanoparticles and plasma proteins , 2012, Analytical and Bioanalytical Chemistry.

[114]  D. K. Yi,et al.  Role of surface modification in zinc oxide nanoparticles and its toxicity assessment toward human dermal fibroblast cells , 2014, International journal of nanomedicine.

[115]  Bengt Fadeel,et al.  Clear and present danger? Engineered nanoparticles and the immune system. , 2012, Swiss medical weekly.

[116]  Kostas Kostarelos,et al.  The long and short of carbon nanotube toxicity , 2008, Nature Biotechnology.

[117]  Andrzej S Pitek,et al.  Reversible versus irreversible binding of transferrin to polystyrene nanoparticles: soft and hard corona. , 2012, ACS nano.

[118]  Xiaoyang Xu,et al.  Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. , 2014, Advanced drug delivery reviews.

[119]  S. Ahmadian,et al.  Toxicity and interaction of titanium dioxide nanoparticles with microtubule protein. , 2008, Acta biochimica et biophysica Sinica.

[120]  Kent E. Pinkerton,et al.  Meeting Report: Hazard Assessment for Nanoparticles—Report from an Interdisciplinary Workshop , 2007, Environmental health perspectives.

[121]  Stefan Tenzer,et al.  Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. , 2013, Nature nanotechnology.

[122]  Martin Lundqvist,et al.  Nanoparticles: Tracking protein corona over time. , 2013, Nature nanotechnology.

[123]  N. Kotov,et al.  Inhibition of amyloid peptide fibrillation by inorganic nanoparticles: functional similarities with proteins. , 2011, Angewandte Chemie.

[124]  Edouard C. Nice,et al.  Differential roles of the protein corona in the cellular uptake of nanoporous polymer particles by monocyte and macrophage cell lines. , 2013, ACS nano.

[125]  Nancy A. Monteiro-Riviere,et al.  Challenges for assessing carbon nanomaterial toxicity to the skin , 2006 .

[126]  Christian Celia,et al.  Polyethylenimine and chitosan carriers for the delivery of RNA interference effectors , 2013, Expert opinion on drug delivery.

[127]  T. Xia,et al.  Understanding biophysicochemical interactions at the nano-bio interface. , 2009, Nature materials.

[128]  Pentti Tengvall,et al.  Blood interactions with noble metals: coagulation and immune complement activation. , 2009, ACS applied materials & interfaces.

[129]  Ramakrishna Podila,et al.  Formation of a protein corona on silver nanoparticles mediates cellular toxicity via scavenger receptors. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[130]  Xiaoyang Xu,et al.  Cancer Nanomedicine: From Targeted Delivery to Combination Therapy , 2015, Trends in molecular medicine.

[131]  Dan Peer,et al.  Nanoparticles for Imaging, Sensing, and Therapeutic Intervention , 2014, ACS nano.

[132]  Giulio Caracciolo,et al.  Do plasma proteins distinguish between liposomes of varying charge density? , 2012, Journal of proteomics.

[133]  Mark E. Davis,et al.  Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles , 2009, Proceedings of the National Academy of Sciences.

[134]  Anil K Patri,et al.  Protein corona composition does not accurately predict hematocompatibility of colloidal gold nanoparticles. , 2014, Nanomedicine : nanotechnology, biology, and medicine.

[135]  Stefan Tenzer,et al.  Protein corona of nanoparticles: distinct proteins regulate the cellular uptake. , 2015, Biomacromolecules.

[136]  Claus-Michael Lehr,et al.  The Interplay of Lung Surfactant Proteins and Lipids Assimilates the Macrophage Clearance of Nanoparticles , 2012, PloS one.

[137]  Parag Aggarwal,et al.  Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. , 2009, Advanced drug delivery reviews.

[138]  Kanlaya Prapainop,et al.  A chemical approach for cell-specific targeting of nanomaterials: small-molecule-initiated misfolding of nanoparticle corona proteins. , 2012, Journal of the American Chemical Society.

[139]  Oliver Hayden,et al.  No king without a crown--impact of the nanomaterial-protein corona on nanobiomedicine. , 2015, Nanomedicine.

[140]  Sara Linse,et al.  Modeling the Time Evolution of the Nanoparticle-Protein Corona in a Body Fluid , 2010, PloS one.

[141]  Robert Langer,et al.  Targeted nanoparticles for cancer therapy , 2007 .

[142]  Azlan Abdul Aziz,et al.  Merging Worlds of Nanomaterials and Biological Environment: Factors Governing Protein Corona Formation on Nanoparticles and Its Biological Consequences , 2015, Nanoscale Research Letters.

[143]  A. L. Adams,et al.  Identification of rapid changes at plasma-solid interfaces. , 1969, Journal of biomedical materials research.

[144]  Roberto Cingolani,et al.  Effects of cell culture media on the dynamic formation of protein-nanoparticle complexes and influence on the cellular response. , 2010, ACS nano.

[145]  Istvan Toth,et al.  Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation. , 2011, Nature nanotechnology.

[146]  Feng Zhang,et al.  Quantitative analysis of the protein corona on FePt nanoparticles formed by transferrin binding , 2010, Journal of The Royal Society Interface.

[147]  M. Ferrari.  Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[148]  D. Irvine,et al.  Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells , 2015, Science Translational Medicine.

[149]  L. Vroman,et al.  Effect of Adsorbed Proteins on the Wettability of Hydrophilic and Hydrophobic Solids , 1962, Nature.

[150]  Marina A Dobrovolskaia,et al.  Evaluation of nanoparticle immunotoxicity. , 2009, Nature nanotechnology.

[151]  Malcolm L. H. Green,et al.  Complement activation and protein adsorption by carbon nanotubes. , 2006, Molecular immunology.

[152]  Philip M. Kelly,et al.  Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. , 2013, Nature nanotechnology.

[153]  E. Conway,et al.  Modulation of complement activation and amplification on nanoparticle surfaces by glycopolymer conformation and chemistry. , 2014, ACS nano.

[154]  Sara Linse,et al.  Complete high‐density lipoproteins in nanoparticle corona , 2009, The FEBS journal.

[155]  Ran Chen,et al.  Comparison of nanotube-protein corona composition in cell culture media. , 2013, Small.

[156]  Vladimir P Torchilin,et al.  Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[157]  D. Holdstock.  Past, present--and future? , 2005, Medicine, conflict, and survival.